Lonza Group AG (LZAGY)
Lonza Group AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Basel, BS, CH. The stock last traded at $69.63, down 1.62% on the session, giving a market capitalisation of $49.54B. On trailing twelve-month figures it carries a trailing P/E of -367.66, a net margin of -1.7%. Its beta of 0.84 implies it has historically moved less than the broad market.
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
Lonza Group AG is most often compared with the following Healthcare names: